A privately held biopharmaceutical company based in Tokyo, Japan, Anaeropharma Science was established in 2004 to pioneer the development of novel therapeutics to target such a hypoxic environment in solid cancers based on its proprietary platform technology, recombinant bifidobacterium therapeutics. » Read full article
We are presenting our latest research updates at PEGS2014 poster sessions. PEGS2014 is scheduled to be held in Boston, MA from May 5-9, 2014.
Click here for detail.
We have initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent.
Innovation Network Corporation of Japan (INCJ) has determined on a follow-on investment of up to 2.2 billion yen in Anaeropharma. INCJ has made its initial investment of 700 million yen in November 2010.
Anaeropharma’s technology was introduced on Shinano Mainich Shinbun. December 31, 2011
Anaeropharma has successfully completed closing of 700 million yen financing for its clinical trials. The investor – Innovation Network Corporation of Japan (INCJ) plans to continuously contribute to Anaeropharma’s future potential financing.
Anaeropharma Science, Inc. and Eisai Co., Ltd. have concluded an option agreement concerning APS001, a novel anticancer agent currently under development at Anaeropharma Science that utilizes characteristic features of Bifidobacterium longum, as well as an agreement concerning the discovery of novel anticancer agents that utilize Bifidobacterium as a drug delivery system.